TLPH News and Press, Teliphone Corp From 03/06/24

2024-03-06 16:33:30 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals Read the full article on Seeking Alpha ...

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with...

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

Talphera Inc. (TLPH) is expected to report $-0.24 for Q4 2023

2024-03-05 17:35:47 ET Major earnings expected after the bell on Wednesday include: Inovio Pharmaceuticals ( INO ) TriplePoint Venture Growth BDC Corp. ( TPVG ) Curaleaf Holdings ( OTCPK:CURLF ) Vermilion Energy ( VET ) Hudson Technologies ( HDSN ) ...

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members PR Newswire SAN MATEO, Calif. , March 1, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development an...

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 PR Newswire SAN MATEO, Calif. , Feb. 26, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the dev...

2024-02-06 16:57:47 ET Talphera ( NASDAQ: TLPH ) filed a prospectus related to the proposed resale of 7.79 million common shares by the selling stockholders. This prospectus is not an offer to sell these securities Read the full article on Seeking Alpha For f...

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering PR Newswire The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of NiyadȒ...